After dose escalation, 120 mg gilteritinib once daily was chosen for further study. There were 58 participants evaluable for response at this dose, 36 of whom harbored FLT3 mutations. For participants ...
Organization of Cancer Specialists in US Physician Practices and Health Systems After dose escalation, 120 mg gilteritinib once daily was chosen for further study. There were 58 participants evaluable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results